Tue, Sep 30, 2014, 7:12 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ampio Pharmaceuticals, Inc. Message Board

gpost511 9 posts  |  Last Activity: Sep 26, 2014 1:15 PM Member since: Sep 6, 2002
  • Reply to

    Stock Offering

    by edfiggy Sep 25, 2014 9:32 AM
    gpost511 gpost511 Sep 26, 2014 1:15 PM Flag

    Sounds like a plan.
    Let's raise $10M by selling 40M shares at ..25 plus oodles of free warrants.
    Then we can raise another $10M by selling 70M shares at .15 plus oodles of free warrants.
    But why stop there? Follow that up with 100M more shares at .10 plus oodles of free warrants.
    Then we can reverse split 1 for 3 and be back to .30.

    It will be hard to see that large dark cloud from the sewer.

    I wonder how other companies like INO raised $10M by partnering PRECLINICAL compounds or a company like EXAS raised funds by selling shares at over a $billion valuation before anything was approved.
    Cartwright is only able to raise funds at steep discounts to a $20M valuation and by filling shopping bags full of free warrants while possessing an approved product internationally which is on the verge of US approval.

    My Aunt Ruthie or my nephew Josh could raise funds by selling stock at a fraction of market price and filling baskets with free warrants. What is Cartwright needed for?

  • Reply to

    Email to GC sent today, 9/23

    by jennifer_jkarim Sep 23, 2014 3:29 PM
    gpost511 gpost511 Sep 24, 2014 10:18 AM Flag

    I have seen companies sell shares at a premium.
    BDSI comes to mind; "BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty biopharmaceutical company, has closed a transaction with Clinical Development Capital, LLC (“CDC”) pursuant to which $7 million in funds previously committed by CDC in July 2005 to fund the clinical development of BDSI’s flagship BEMATM Fentanyl product have been converted into shares of BDSI common stock at a 40 % premium to the closing price for BDSI’s shares."

    Needless to say, the pps has tripled since then.

  • gpost511 gpost511 Aug 29, 2014 9:02 AM Flag

    The demise of an illusion.

  • gpost511 gpost511 Aug 19, 2014 5:38 PM Flag

    GALE had $39M on June 30th.
    Subsequently Zuplenz was purchased for $5M and there is $4M of debt repayment this year.
    The loss in Q3 will be about $15M.
    So the remaining cash on Sept 30 will be about $15M.
    Another offering will be needed before year end.
    Perhaps Ahn is already shopping one.

  • Reply to

    fair valuation

    by noquickgame Aug 19, 2014 9:30 AM
    gpost511 gpost511 Aug 19, 2014 5:20 PM Flag

    Comparing GALE to the overpriced flavor of the month will get you nowhere. A couple of years ago, message board poster were hyping penny biotechs as the next DNDN.

    Neuvax failed in a P2 trial for Apthera. It should have been written off. GALE ran another P2 trial with cherry picked patients.
    The results:
    Of the 109 women vaccinated with NeuVax, 6.5% had a breast cancer relapse after 24 months of follow up compared to 14.5% of the 79 women in the control group, according to data presented at the 2010 ASCO annual meeting. NeuVax patients had numerically fewer relapses but the trend was not statistically significant, with a p value of 0.08, which exceeded the 5% benchmark typically signifying a positive study.

    Patients in this Phase 2 study were followed longer but the results didn't get any better. After 36 months follow up, the cancer relapse rate for NeuVax-treated women was 8.5% compared to the same 14.5% relapse rate for the control group of women. The relapse rate gap narrowed and the statistics behind the study got worse, with the p value growing to 0.187.

  • gpost511 gpost511 Aug 19, 2014 5:04 PM Flag

    Did you believe the DreanTeanm hype?
    Abstral was a flop for Orexo.
    It wasn't able to capture even 1% market share after two years of trying.
    The fentanyl market is declining.
    There is lots of entrenched competition and generics.
    Besides, the patent expires in 2019.
    Why did you choose to believe the DreamTeam and Seeking Alpha pumpers and not the facts?

    The $900,000 was pushed into this quarter to reach $2M in sales which means the that $900,000 is coming out of next quarter. They deferred the really bad news for one quarter. Q3 sales will be in the $1M range.

  • Reply to

    fair valuation

    by noquickgame Aug 19, 2014 9:30 AM
    gpost511 gpost511 Aug 19, 2014 4:50 PM Flag

    PBYI has $180M of cash. PBYI has a partnership with Pfizer. PBYI reported a successful P3 trial. That's not to say that PBYI isn't overpriced at this level as GALE was at $7.77. Stocks run up and get overvalued as GALE did earlier.

    GALE is late to the game and NeuVax has little chance of being successful. It already failed in a P2 trial. Data mining is a shell game. What else does GALE have, a couple of discards from other companies that are cash drains?

    What does PBYI have?
    "drug candidates include PB272 (neratinib (oral)) for the treatment of advanced breast cancer patients, non-small cell lung cancer patients, and patients with HER2 mutation-positive solid tumors; and PB272 (neratinib (intravenous)) for the treatment of advanced cancer patients. The company is also developing PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds."

    You really should stop posting and crawl back under your rock.
    If somebody pumps a penny shell oil stock and compares it to Exxon, spit in their eye.
    If somebody pumps a penny tech stock and compares it to AAPL, spit in their eye.

  • Reply to

    bashers are funny!!!

    by lovejoycraig Aug 3, 2014 1:16 PM
    gpost511 gpost511 Aug 3, 2014 1:22 PM Flag

    You should move on.
    $200.00 to $9.75, two reverse splits, and nothing developed in 35 years isn't a stock that you should be pumping to the moms and pops.

  • gpost511 gpost511 Aug 3, 2014 1:21 PM Flag

    Yeah, but when the missing patients when included in the data, sway the results such that the endpoints are not met, the trial is disappointing, inconclusive, suspect .......

3.53-0.19(-5.11%)Sep 30 4:04 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.